Completed NA INTERVENTIONAL 2-arm NCT05058755

Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma

Efficacy and Safety of Tislelizumab Combined Treatment in Refractory Natural Killer/T-cell Lymphoma

Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Conditions Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Interventions tislelizumab, azacytidine, lenalidomide tislelizumab, etoposide, pegaspargase

Updated 5 times since 2021 Last updated: Feb 29, 2024 Started: Sep 17, 2021 Primary completion: Dec 30, 2022 Completion: Dec 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05058755, this NA trial focuses on Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type and remains completed. Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, it has been updated 5 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Apr 2024 — Jul 2024 [monthly]

Completed NA

Status: Unknown Status → Completed
Feb 2024 — Apr 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Oct 2021 — Feb 2024 [monthly]

Recruiting NA

First recorded

Sep 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Data source: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China